Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/exd.14731 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of bronchial biopsy in the prediction of response to biological therapy in severe uncontrolled asthma: a prospective study.
Chest
December 2024
Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain.
Background: Up to two thirds of patients with severe uncontrolled asthma (SUA) who received biological therapy do not have a complete response.
Research Question: Can bronchial biopsy (BB) play a role in the identification of patients with SUA who has a better response to biological therapy?
Study Design: AND METHODS: Prospective multicentre study. Consecutive SUA patients candidate to biological therapy underwent bronchoscopy and BB prior to biological therapy and clinical response was evaluated 6 months later.
The effect of benralizumab on inflammation in severe asthma: a real-life analysis.
Ther Adv Respir Dis
December 2024
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.
Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.
Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with mepolizumab.
J Asthma
January 2025
Department of Allergy, Hospital La Paz, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.
Response to biologics in severe uncontrolled asthma (SUA) can be classified as super-responders, good responders, non-responders, and those achieving clinical remission. The aim of this study is to evaluate the long-term response to mepolizumab in patients with severe eosinophilic asthma and assesses the rate of asthma clinical remission over four years in a real-life setting. This is a single-center, observational, retrospective study was conducted at La Paz University Hospital (Madrid, Spain) from 2017 to 2022.
View Article and Find Full Text PDFIdentifying super-responders: A review of the road to asthma remission.
Ann Allergy Asthma Immunol
January 2025
Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address:
Article Synopsis
- Asthma is a complex and chronic respiratory condition that shows a wide range of symptoms and treatment responses, with some patients achieving a state known as 'remission.'
- The review delves into the factors that hinder remission, such as Type 2 inflammation, obesity, and poor treatment adherence, and emphasizes the long-term impacts of the disease burden on patients.
- The authors propose a "Predict and Prevent" strategy for early identification and aggressive treatment of high-risk asthma patients to enhance recovery prospects, while also calling for a clearer definition of asthma remission and further research on effective treatment strategies.
Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study.
J Clin Med
July 2024
Agrippa Ionescu Emergency Clinical Hospital, 011773 Bucharest, Romania.
: Psoriasis is an immune-mediated chronic disorder associated with various comorbidities. Even though biologics and small-molecule inhibitors are the mainstay treatment for moderate-to-severe psoriasis, there is no current consensus regarding which agent should be used for a specific type of patient. This paper aims to test the reliability of blood-count-derived inflammatory markers in assessing treatment response to biologics and small-molecule inhibitors in psoriasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!